STAT3 inhibiting compositions and methods

Details STAT3 inhibiting compositions and methods STAT3 inhibiting compositions and methods

2010-12-10

2011-11-15

Spivack, Phyllis G. (Department: 1629)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

C-o-group doai

Reexamination Certificate

active

08058316

ABSTRACT:
A composition may include a pharmaceutical carrier and an amount, therapeutically effective for the treatment of a retinal disease, of CLT-005 (1-acetyl-5-hydroxyanthracene-9,10 -dione), wherein the retinal disease is characterized by at least one of inflammation, angiogenesis, or neovascularization, and wherein the composition is prepared for administration intravitreally. The composition may be administered intravitreally to a subject's eye.

REFERENCES:
patent: 5316768 (1994-05-01), Hughes et al.
patent: 7279469 (2007-10-01), Pierce et al.
patent: 7307069 (2007-12-01), Karras
patent: 2006/0247318 (2006-11-01), Song et al.
patent: 2007/0060521 (2007-03-01), Jove et al.
patent: 2006/091837 (2006-08-01), None
Hohman, T.C., Retina, (Jun. 2009), 29(6 Suppl.), S51-3(Abstract).
Huang, et al., “Synthesis and antitumor evaluation of symmetrical 1,5-diamidoanthraquinone derivatives as compared to their disubstituted homologues.,” Chem. Pharm. Bulletin, Apr. 2006, vol. 54, No. 4, pp. 458-464, the Pharmaceutical Society of Japan (Tokyo).
Johnson, et al., “Antitumor agents-CLXVII Synthesis and structure-activity correlations of the cytotoxic antraquinone 1.4-bis-(2,3-epoxypropylamino)-9,10-anthracenedione, and of related compounds.” Bioorganic & Medicinal Chemistry, Aug. 1997, vol. 5, No. 8, pp. 1469-1479, Elsevier (NL).
Kaiser, P.K., Trans. Am. Ophth. Soc., (Dec. 2009), 107: 311-24 (abstract).
St. Pyrek, et al., “Naphto- and Anthraquinones of Streptomyces Thermoviolaceus WR-141. Structures and Model Syntheses,” Tetrahedon, 1977, pp. 673-680, vol. 33, Issue 6, Pergamon Press Published in United Kingdom.
Teng, et al., “Design, synthesis and cytotoxic effect of hydroxy- and 3-alklylaminopropoxy-9,10-anthraquinone derivatives,” Bioorganic & Medicinal Chemistry, May 16, 2005, vol. 13, No. 10, pp. 3439-3445, Elsevier (Netherlands).
Turkson, et al., “Novel peptidomimetic inhibitors of signal transducer and activator of transcription 3 dimerization and biological activity,” Molecular Cancer Therapeutics, Mar. 2004;3(3):261-9, American Association for Cancer Research, Philadelphia (US).

Affiliated with

Also associated with

Rating

STAT3 inhibiting compositions and methods does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with STAT3 inhibiting compositions and methods, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and STAT3 inhibiting compositions and methods will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4310588